Biontech announces first quarter 2024 financial results and corporate update

Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in phase 3 clinical trial evaluating bnt323/db-1303 in hr+ her2-low chemotherapy-naÏve metastatic breast cancer patients, and a second phase 3 trial with bnt323/db-1303 in recurrent endometrial cancer planned to start soon presented clinical data at the american association for cancer research (“aacr”) annual meeting for individualized and off-the-shelf mrna-based cancer vaccine candidates based on inest and fixvac platforms, including three-year follow-up data of an investigator-initiated trial in patients with resected pancreatic ductal adenocarcinoma (“pdac”) planning to share additional clinical data from multiple clinical programs at the american society of clinical oncology (“asco”) annual meeting, including bispecific antibodies bnt311/gen1046 (acasunlimab) and bnt327/pm8002 and antibody-drug conjugate (“adc”) bnt326/yl202 continued development and commercial preparation for a 2024 season variant-adapted covid-19 vaccine first quarter 2024 revenues of €187.6 million, net loss of €315.1 million an d loss per share of €1.31 ($1.421) maintained strong financial position with €16.9 billion in cash, cash equivalents and security investments conference call and webcast scheduled for may 6, 2024, at 8:00 a.m. edt (2:00 p.m.
BNTX Ratings Summary
BNTX Quant Ranking